Striatal volume deficits in children with ADHD who present a poor response to methylphenidate

Moreno, Amparo; Duñó, Lurdes; Hoekzema, Elseline; Picado, Marisol; Martin, Lene; Fauquet, Jordi; Vives-Gilabert, Yolanda; Bulbena, Antoni; Vilarroya, Óscar

doi:10.1007/s00787-013-0510-y

Cited by 21 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonresponsive patients to MPH therapy can reach up to 30% of ADHD patients. The reasons for this unresponsiveness are still unknown and presently no clinical or biological markers have been found that could distinguish good from poor responders to MPH (Moreno et al, 2014). No responsiveness could reflect interindividual differences, namely very low DA activity, differences in the sensitivity or levels of DAT, differences in sensitivity of postsynaptic DA receptors and/or differences in the noradrenergic activity (Volkow et al, 2002, 2005).…”

Section: Methylphenidate (Mph)mentioning

confidence: 99%

“…This means that patients that do not respond adequately to MPH treatment are excluded from these studies. A recent study evaluated whether striatal differences exist between good and poor responders to MPH, in a sample that included 27 treatment‐naive children with ADHD aged between 6 and 14 (19 males and 8 females) (Moreno et al, 2014). After a month of MPH treatment, psychiatrists established that 16 patients showed good response to MPH and 11 a poor one.…”

Section: Methylphenidate (Mph)mentioning

confidence: 99%

“…After a month of MPH treatment, psychiatrists established that 16 patients showed good response to MPH and 11 a poor one. The MRI scans revealed that the good responder group had a higher concentration of gray matter in the head of both caudate nuclei and the right nucleus accumbens (Moreno et al, 2014). The acute and long‐term brain consequences of keeping the medication of an ADHD patient with MPH, despite being a non‐responder, are presently not established.…”

Section: Methylphenidate (Mph)mentioning

confidence: 99%

See 2 more Smart Citations

Methylphenidate effects in the young brain: friend or foe?

Loureiro-Vieira

Costa

Bastos

et al. 2017

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neuropsychiatry disorders in children and adolescents, and methylphenidate (MPH) is a first-line stimulant drug available worldwide for its treatment. Despite the proven therapeutic efficacy, concerns have been raised regarding the possible consequences of chronic MPH exposure during childhood and adolescence. Disturbances in the neurodevelopment at these crucial stages are major concerns given the unknown future life consequences. This review is focused on the long-term adverse effects of MPH to the brain biochemistry. Reports conducted with young and/or adolescent animals and studies with humans are reviewed in the context of long-term consequences after early life-exposure. MPH pharmacokinetics is also reviewed as there are differences among laboratory animals and humans that may be relevant to extrapolate the findings. Studies reveal that exposure to MPH in laboratory animals during young and/or adolescent ages can impact the brain, but the outcomes are dependent on MPH dose, treatment period, and animal's age. Importantly, the female sex is largely overlooked in both animal and human studies. Unfortunately, human reports that evaluate adults following adolescent or child exposure to MPH are very scarce. In general, human data indicates that MPH is generally safe, although it can promote several brain changes in early ages. Even so, there is a lack of long course patient evaluation to clearly establish whether MPH-induced changes are friendly or foe to the brain and more human studies are needed to assess the adult brain changes that arise from early MPH treatment.

show abstract

Section: Methylphenidate (Mph)mentioning

confidence: 99%

Section: Methylphenidate (Mph)mentioning

confidence: 99%

Section: Methylphenidate (Mph)mentioning

confidence: 99%

See 1 more Smart Citation

Methylphenidate effects in the young brain: friend or foe?

Loureiro-Vieira

Costa

Bastos

et al. 2017

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

show abstract

“…No obstante, la muestra del estudio es reducida, por lo que estos resultados deben considerarse como pre liminares. Por último, otro estudio transversal con niños con TDAH llevado a cabo recientemente su giere la implicación de los núcleos caudado y accumbens no sólo en el control inhibitorio, sino tam bién en el funcionamiento atencional [19].…”

Section: Correlato Entre La Neuroanatomía Y La Neuropsicologíaunclassified

“…Los datos de estudios transversales asocian los síntomas de TDAH, ya sea de manera conjunta o por separado, con una relativa amplia variedad de regiones cerebrales. Mayores niveles de inatención también se han vinculado a nivel subcortical con el volumen de las regiones talámicas [28], núcleos caudado y accumbens [19], y cerebelo [29]. A nivel cortical, también se han encontrado relaciones en tre las regiones prefrontales y los síntomas de in atención [30].…”

Section: Correlato Entre La Neuroanatomía Y La Clínicaunclassified

Neuroanatomía del trastorno por déficit de atención/hiperactividad: correlatos neuropsicológicos y clínicos

Albert¹,

Fernández-Jaén²,

Fernández-Mayoralas³

et al. 2016

RevNeurol

View full text Add to dashboard Cite

Aim. To explore the relation between neuroanatomy, clinical features and neuropsychology in ADHD. Development. At group level, there are a number of marked differences between the brain of children, adolescents and adults with ADHD and the brain of subjects with a typical development. These differences are observed cross-sectionally and longitudinally in all the measurements, both in the grey matter and in the white matter. Although still scarce, there is an increasing body of evidence showing that these differences are related with the core symptoms of the disorder and with the degree of clinical dysfunction. They also appear to be associated with cognitive functioning (mainly attention and inhibitory control). Conclusions. The relation among the different levels of analysis in the study of ADHD bring research closer to the clinical features and allows a better understanding and management of the disorder. Although progress is undoubtedly being made in this field, there are still many questions that need exploring in greater depth. There is a need for a better understanding of the association between the neuroanatomical measurements and each dimension of the symptoms, and their relationship with other neuropsychological processes that are also involved in the disorder.

show abstract